Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 11 recruiting clinical trials
Newly diagnosed MM – Maintenance
(following ASCT)
(following ASCT)
MajesTEC-4
Phase
NCT05243797
Compound
Teclistamab (BCMA × CD3 bispecific Ab) ± lenalidomide
Newly diagnosed MM (not candidate for or deferred ASCT)
MajesTEC-7
Phase
NCT05552222
Compound
Teclistamab (BCMA × CD3 bispecific Ab) or talquetamab (GPRC5D × CD3 bispecific Ab) + daratumumab (anti-CD38 mAb) + lenalidomide
Relapsed or refractory MM (≥3 prior LOT)
MonumenTAL-1
Phase
NCT04634552
Compound
Talquetamab (GPRC5D × CD3 bispecific Ab)
MM
Talisman
Phase
NCT06500884
Compound
Talquetamab (GPRC5D × CD3 bispecific Ab) + prophylaxis A/B/C/D or ramantamig (BMA × GPRC5D × CD3 trispecific Ab)
Relapsed or refractory MM (≥3 prior LOT) or previously treated AL amyloidosis (≥1 prior LOT)
MMY1001
Phase
NCT05652335
Compound
Ramantamig (BCMA × GPRC5D × CD3 trispecific Ab)
MM (1–3 prior LOT)
MMY1002
Phase
b
NCT06768489
Compound
JNJ-79635322 (BCMA × GPRC5D × CD3 trispecific Ab) + daratumumab (anti-CD38 mAb) or pomalidomide or daratumumab + lenalidomide
MM (previously treated with cilta-cel in a clinical trial)
CARTinue
Phase
NCT05201781
Compound
No intervention (previously received cilta-cel [anti-BCMA CAR T-cell therapy])
MM
CARTITUDE-10
Phase
NCT07149857
Compound
Cilta-cel (anti-BCMA CAR T-cell therapy) + cyclophosphamide + induction therapy
Relapsed or refractory MM
87562761MMY1001
Phase
NCT06604715
Compound
JNJ-87562761
Relapsed or refractory MM (≥3 prior LOT)
Trilogy-3
Phase
NCT07266441
Compound
Ramantamig (BCMA × GPRC5D × CD3 trispecific Ab)
Relapsed or refractory MM (≥3 prior LOT)
Trilogy-4
Phase
NCT07258511
Compound
Ramantamig (BCMA × GPRC5D × CD3 trispecific Ab) or teclistamab (BCMA × CD3 bispecific Ab)
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency. Teclistamab and talquetamab include technology licensed from Genmab A/S. Cilta-cel is developed in collaboration with Legend Biotech.
Ab, antibody; AL, amyloid light chain; ASCT, autologous stem cell transplant; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; CD, cluster of differentiation; GPRC5D, G protein-coupled receptor class C group 5 member D; LOT, lines of therapy; mAb, monoclonal antibody; MM, multiple myeloma.